Financials ClearPoint Neuro, Inc.
Equities
CLPT
US18507C1036
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.89 USD | -0.84% | +8.47% | -13.25% |
May. 07 | ClearPoint Neuro, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 07 | Earnings Flash (CLPT) CLEARPOINT NEURO Reports Q1 Revenue $7.6M, vs. Street Est of $7M | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 72.99 | 268.1 | 265.2 | 208 | 167.2 | 159.4 | - | - |
Enterprise Value (EV) 1 | 72.99 | 268.1 | 265.2 | 208 | 167.2 | 159.4 | 159.4 | 159.4 |
P/E ratio | -11.4 x | -37 x | -16.3 x | -12.5 x | -7.54 x | -7.78 x | -8.33 x | -9.06 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 6.51 x | 20.9 x | 16.3 x | 10.1 x | 6.98 x | 5.27 x | 3.73 x | 2.76 x |
EV / Revenue | 6.51 x | 20.9 x | 16.3 x | 10.1 x | 6.98 x | 5.27 x | 3.73 x | 2.76 x |
EV / EBITDA | - | -55.9 x | -23.8 x | -17.4 x | -10.6 x | -12.3 x | -15.2 x | -30.7 x |
EV / FCF | - | -32.3 x | - | - | -11.6 x | -12.5 x | -23.9 x | - |
FCF Yield | - | -3.09% | - | - | -8.64% | -8% | -4.19% | - |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 15,206 | 16,870 | 23,640 | 24,555 | 24,621 | 27,070 | - | - |
Reference price 2 | 4.800 | 15.89 | 11.22 | 8.470 | 6.790 | 5.890 | 5.890 | 5.890 |
Announcement Date | 2/12/20 | 3/4/21 | 3/1/22 | 3/1/23 | 3/12/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 11.22 | 12.83 | 16.3 | 20.55 | 23.96 | 30.26 | 42.77 | 57.8 |
EBITDA 1 | - | -4.796 | -11.14 | -11.96 | -15.74 | -13 | -10.5 | -5.2 |
EBIT 1 | - | -6.22 | -13.37 | -16.33 | -22.45 | -20.81 | -19.75 | -18.8 |
Operating Margin | - | -48.48% | -82.05% | -79.47% | -93.7% | -68.76% | -46.18% | -32.53% |
Earnings before Tax (EBT) 1 | - | -6.782 | -14.41 | -16.44 | -22.09 | -20.33 | -19.28 | -17.9 |
Net income 1 | - | -6.782 | -14.41 | -16.44 | -22.09 | -20.33 | -19.28 | -17.9 |
Net margin | - | -52.86% | -88.41% | -79.97% | -92.21% | -67.19% | -45.07% | -30.97% |
EPS 2 | -0.4200 | -0.4300 | -0.6900 | -0.6800 | -0.9000 | -0.7567 | -0.7067 | -0.6500 |
Free Cash Flow 1 | - | -8.29 | - | - | -14.44 | -12.75 | -6.678 | - |
FCF margin | - | -64.62% | - | - | -60.27% | -42.15% | -15.61% | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 2/12/20 | 3/4/21 | 3/1/22 | 3/1/23 | 3/12/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 4.574 | 4.3 | 5.031 | 5.2 | 5.146 | 5.174 | 5.433 | 5.95 | 5.762 | 6.81 | 7.639 | 7.32 | 7.691 | 8.255 |
EBITDA 1 | -3.167 | -3.011 | -2.879 | -3.223 | -2.583 | -3.277 | -4.276 | -5.33 | -3.155 | -2.98 | -2.484 | -3.95 | -2.6 | -2.85 |
EBIT 1 | -3.804 | -3.982 | -3.864 | -4.204 | -3.795 | -4.469 | -5.712 | -7.131 | -4.897 | -4.706 | -4.231 | -5.588 | -4.907 | -5.162 |
Operating Margin | -83.17% | -92.6% | -76.8% | -80.85% | -73.75% | -86.37% | -105.14% | -119.85% | -84.99% | -69.1% | -55.39% | -76.34% | -63.81% | -62.53% |
Earnings before Tax (EBT) 1 | -3.98 | -4.149 | -3.959 | -4.303 | -3.788 | -4.385 | -5.609 | -7.052 | -4.809 | -4.619 | -4.146 | -5.436 | -4.791 | -5.079 |
Net income 1 | -3.98 | -4.149 | -3.959 | -4.303 | -3.788 | -4.385 | -5.609 | -7.052 | -4.809 | -4.619 | -4.146 | -5.436 | -4.791 | -5.079 |
Net margin | -87.01% | -96.49% | -78.69% | -82.75% | -73.61% | -84.75% | -103.24% | -118.52% | -83.46% | -67.83% | -54.27% | -74.27% | -62.29% | -61.52% |
EPS 2 | -0.1800 | -0.1900 | -0.1700 | -0.1800 | -0.1500 | -0.1800 | -0.2300 | -0.2900 | -0.2000 | -0.1900 | -0.1600 | -0.2033 | -0.1800 | -0.1867 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/9/21 | 3/1/22 | 5/11/22 | 8/9/22 | 11/8/22 | 3/1/23 | 5/11/23 | 8/8/23 | 11/9/23 | 3/12/24 | 5/7/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -8.29 | - | - | -14.4 | -12.8 | -6.68 | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | - | - | - | - | 0.72 | 0.25 | 0.25 | - |
Capex / Sales | - | - | - | - | 2.99% | 0.84% | 0.59% | - |
Announcement Date | 2/12/20 | 3/4/21 | 3/1/22 | 3/1/23 | 3/12/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.25% | 159M | |
+7.93% | 219B | |
+7.53% | 184B | |
+15.20% | 138B | |
+27.02% | 108B | |
-1.14% | 62.54B | |
+7.23% | 52.22B | |
+12.58% | 51.73B | |
+1.61% | 41.4B | |
+5.32% | 37.17B |
- Stock Market
- Equities
- CLPT Stock
- Financials ClearPoint Neuro, Inc.